Feeley Kevin 4

What Happened

• Kevin Feeley, Chief Financial Officer of GeneDx (WGS), had 16,250 restricted stock units (RSUs) convert to 16,250 shares on March 26, 2026 (acquired at $0 per share). To satisfy tax withholding tied to that vesting, he sold a portion of the shares in multiple open-market transactions, disposing of 8,818 shares for total reported proceeds of $557,051. The filing records both the RSU conversion (derivative exercise/conversion) and the subsequent share sales; these were sell-to-cover transactions rather than discretionary stock sales.

Key Details

• Transaction date: March 26, 2026 (Form 4 filed 2026-03-30).
• RSU conversion: 16,250 shares acquired at $0.00 (per footnote: RSUs convert to 1 share each upon settlement for no consideration).
• Open-market sales (weighted average prices and reported price ranges):
  • 2,485 shares at $61.29 (range $60.93–$61.91)
  • 961 shares at $62.33 (range $61.93–$62.91)
  • 2,520 shares at $63.28 (range $62.96–$63.955)
  • 995 shares at $64.60 (range $63.99–$64.96)
  • 1,857 shares at $65.21 (range $65.00–$65.61)
• Total open-market proceeds: ~$557,051.
• Holdings after the transactions (per filing): 34,580 shares beneficially owned, plus RSUs representing rights to up to 93,173 additional shares and options for up to 25,906 shares (these awards vest per their terms).
• Notable footnotes: sales were to satisfy tax withholding obligations (sell-to-cover) and were not discretionary (F2); weighted-average prices reported with per-tranche price ranges (F3–F7). No late filing is indicated on the form.

Context

• RSUs: represent a contingent right to receive one share each upon settlement (no purchase price), and vesting here triggered tax withholding. Sell-to-cover transactions are routine to fund withholding and are not necessarily a signal of changing insider sentiment. The RSU award vests 25% annually (first tranche vested March 26, 2025), and remaining RSUs/options vest over time per the award terms.